Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

28-05-2021 | Empagliflozin | News

approvalsWatch

Empagliflozin gets positive CHMP decision for heart failure

Author: Eleanor McDermid

print
PRINT
insite
SEARCH

medwireNews: Empagliflozin is on track to expand its indication in the EC to include heart failure, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).

The expanded indication will cover adults with symptomatic heart failure with reduced ejection fraction, irrespective of the presence of type 2 diabetes.

It follows the 2020 publication of the EMPEROR-Reduced trial, which found a significant 25% reduction in the risk for death from cardiovascular causes or hospitalization for heart failure with empagliflozin versus placebo in this patient group.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Related content

29-03-2021 | Empagliflozin | News

Diuresis ‘not dominant’ mediator of SGLT2 inhibitors’ cardiac benefits

09-02-2021 | Empagliflozin | News

Empagliflozin gains occur on top of neprilysin inhibitor benefits in HF

18-11-2020 | Heart failure | News

Empagliflozin shows heart failure benefits regardless of HbA1c

20-01-2021 | Empagliflozin | News

EMPA-TROPISM: Empagliflozin improves LV remodeling in patients with heart failure
Image Credits